Ethris and Heqet Therapeutics have revealed plans to collaborate on RNA-based therapeutics for heart attack and heart failure, using non coding RNAs (ncRNAs) in regenerating heart tissue. Under the terms of the agreement, Heqet Therapeutics will lead the development of the programme, while Ethris will provide its proprietary Stabilized NanoParticle (SNaP) LNP platform to deliver […]
